Health Condition 1: C950- Acute leukemia of unspecified celltype
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Indian Council of Medical Research (ICMR)
Jawaharlal Institute of Postgraduate Medical Education Research JIPMER
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria a) All newly diagnosed patients with acute leukemia who are registered in the Department of Medical Oncology b) Either a diagnosis of ALL, AML, or APML c) Patients who are treatment naive d) All age groups and gender
Exclusion criteria
Exclusion criteria: Exclusion criteria a) patients who refuse to give consent b) pregnant women with acute leukemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Establish a biorepository for acute leukemia with well-annotated clinical data.Timepoint: 1. Baseline at diagnosis[T1] 2. At remission (21-28 days) [T2] 3. At treatment completion (if feasible)[T3] 4. At relapse (where applicable)[T4] | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Augment in-house laboratory capacity in leukemia-specific advanced investigations 2. Support the conduct of local need-based translational studies for high-risk and relapsed/refractory acute leukemia in the focused areas defined in the CAR project. 3. Provide a platform to conduct future studies investigating different biological and clinical aspects of this rare but potentially curable malignancy and eventually become a resource for clinicians, and basic scientists.Timepoint: 1. Baseline at diagnosis[T1] 2. At remission (21-28 days) [T2] 3. At treatment completion (if feasible)[T3] 4. At relapse (where applicable)[T4] | — |
Countries
India
Contacts
Public ContactDr Smita Kayal
Jawaharlal Institute of Postgraduate Medical Education & Research
Outcome results
None listed